This institute is comprised of more than 60 faculty researchers, surgeons, oncologists, residents and post-graduate fellows. All are committed to achieving excellence in patient care, advancing medicine and educating the physicians of tomorrow through resident and fellowship programs.
Dr. Inderbir Gill is the Chairman and Professor of the Catherine and Joseph Aresty Department of Urology, Founding Executive Director of the USC Institute of Urology and Associate Dean for Clinical Innovation. He also holds the Hanson-White Chair. Dr Gill has received many honors. In 2005, the President of India awarded him the Dr. B. C. Roy National Award for Eminent Medical Person. In 2006, he was awarded the St. Paul's Medal by the British Urological Association (BAUS) for 2006, the highest honor that can be bestowed by the BAUS. He has been named honorary Fellow of the Royal College of Surgeons of England. In 2006, he was President of the 24th World Congress of Endourology and SWL, and organized in Cleveland one of the most successful world congresses to date, with more than 1700 attendees from 62 countries. He was awarded the "USC Presidential Medallion" for 2013, the highest annual academic honor that USC can bestow from amongst the 40,000 faculty/students from all 19 of USC's schools. He has been listed amongst "Best Doctors in America" for several years now. His minimally invasive team has won over 35 best abstract awards at various annual meetings of the AUA and other urologic societies over the past 5-7 years. He was named Ramon Guiteras Lecturer at the 2015 AUA annual meeting in New Orleans. Dr. Gill's primary focus is advanced robotic urologic oncologic surgery, with one of the world's largest aggregate robotic/laparoscopic experiences in approx 9,000 cases in the United States. A world leader in robotic/laparoscopic partial nephrectomy for renal cancer, he and his team have performed this procedure in over 2,500 patients, the world's largest series. His team's scientific innovations in robotic & laparoscopic oncologic surgery have generated world-leading clinical series of radical cystectomy with intra-corporeal urinary diversion (n=200 ), radical prostatectomy (n= 6,000 ) and renal cryoablation. Over the past 3 years, Dr Gill and his team are focusing on developing novel image-guided targeted biopsy and lesion-specific focal therapy treatments for prostate cancer. He has published more than 619 peer-reviewed scientific papers, 55 book chapters and eleven textbooks and has been on the editorial board of nine urologic journals. Funded by the NCI, he has been invited for over 450 visiting professorships, invited lectures, and live surgery demonstrations world-wide.He is elected to the prestigious American Association of Genito-Urinary Surgeons (2003) and the clinical society of AAGUS (2009).